| Date | Title | Description |
| 15.01.2025 | SV Therapeutics 2024 Year in Review | Looking back at 2024 – an excellent year for SV’s Therapeutics Funds
As members of our team gather with the biotech community in San Francisco for the annual JP Morgan Healthcare conference to look to the year ahead, SV is thrilled to provi... |
| 09.01.2025 | Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS | Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform.
CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ -- Alchemab Therapeutics (Alchemab), a bioph... |
| 26.12.2024 | Kate Bingham on innovation in drug development on World at One Radio 4 | Kate Bingham discusses the effect of accelerating rates of innovation in drug development driven by an increasing rate of scientific discovery and AI tools, is improving drug development timelines and patient outcomes in a recent interview ... |
| 19.12.2024 | SV Health Investors Promotes A.J. Rossi to Partner on Healthcare Growth-Buyout Team | [BOSTON and LONDON, 19 December 2024] SV Health Investors (“SV”), a leading healthcare-focused private equity firm, is pleased to announce the promotion of A.J. Rossi to Partner on the firm’s Growth-Buyout team. In this new role, A.J. will ... |
| 16.12.2024 | 2024 SV Therapeutics Impact & ESG Report | 2023 SV Therapeutics Impact & ESG Report (click to view)
At SV, we invest in biotech companies developing innovative therapeutics based on novel science to address critical unmet medical needs. These companies have the potential to chan... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 04.12.2024 | Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors | - Lilly is granted exclusive worldwide rights to develop a CD28-co-stimulatory therapeutic for a defined cancer target
– Rondo Therapeutics receives upfront cash and is eligible to receive milestone payments and tiered royalties
December 04... |
| 02.12.2024 | Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 | - SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases.
- Phase 1 clinical trial supported by preclinical data demonstrating high potency,... |
| 24.11.2024 | Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas | CHANHASSEN, Minn., Nov. 24, 2024 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced positive results from their Pha... |
| 14.11.2024 | TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development | SOUTH SAN FRANCISCO, November 13, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84 million Series B fina... |
| 31.10.2024 | SV is hiring: Executive Assistant | Position Title: Executive Assistant – Venture Capital/Growth Equity Firm
Location: Boston Office (w/hybrid WFH and in-office schedule – current expectations are 2 days/week in office)
Reports to: Partner
Effective Date: Immediate
About the ... |
| 08.10.2024 | Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System | Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
Underlying proof of rejuvenative healing indicative of airway remodeling corresponds wi... |
| 08.10.2024 | Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases | – Exclusively deploys Mestag’s proprietary RAFT platform to interrogate the pathogenic role of fibroblasts in inflammatory disease for novel target discovery
Cambridge, UK, October 8, 2024 – Mestag Therapeutics (“Mestag”), a biotech company... |
| 08.10.2024 | Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications | LONDON, and TOKYO, – October 8, 2024 – AviadoBio Ltd. (“AviadoBio”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced an exclusive option and license agreement for AVB-101, an investigational... |
| 03.10.2024 | Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens® | Oxford, United Kingdom – October 3, 2024. Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. The round was co-led by new investors, Pfizer Ventu... |
| 02.10.2024 | LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington's disease | Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy ... |
| 24.09.2024 | Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership with eXmoor pharma | London, UK and Bristol, UK, 24 September 2024 –Quell Therapeutics Ltd (“Quell” or “the Company”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, and eXm... |
| 19.09.2024 | Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative dise... |
| 18.09.2024 | Navigating the $100B+ Alzheimer's Market | Laurence Barker, Partner at The Dementia Discovery Fund - SV Health Investors | Explore the transformative advancements in Alzheimer's research with expert Laurence Barker. Understand why the next decade could see significant leaps in dementia treatment and how early intervention plays a crucial role. Get insights on t... |
| 11.09.2024 | SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System | BEDFORD, Mass.--(BUSINESS WIRE)--SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), today announced a $50M Series B funding round led by Johnson &... |
| 09.09.2024 | Eyes on the target: Drug discovery’s new paradigm | Back to School 2024: Can biotech write a more successful playbook for translating from target to product? |
| 09.09.2024 | Neurology’s human data revolution | Back to School 2024 looks at how neuroscience companies are reducing to practice the concept of human-first discovery |
| 03.09.2024 | Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review | Pridopidine’s Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) is the first submission for approval for an investigational new treatment for adults with Huntington’s disease (HD) with potential to impact dise... |
| 03.09.2024 | Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer | Cambridge, UK, 3 September 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the appointment of Antony Mattessich as its Chief Executive Of... |
| 28.08.2024 | Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 | – Innovate UK, part of UK Research and Innovation, is investing £12 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to Mestag
– Bispecific antibody MST-0300 is a f... |
| 12.08.2024 | Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, oper... | MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of ... |
| 06.08.2024 | Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated Op... | ST. PAUL, Minn.--(BUSINESS WIRE)--Spineology, the medical device company pioneering Conform and Expand™ spinal fusion technology, today announced that it has raised $25 million in Series AA financing led by SV Health Investors, with partici... |
| 30.07.2024 | Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fund and Two Bear Capital to Develop Safer, More Effective Neuroscience Drugs Using a Novel Brain-Only ... | SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- Montara Therapeutics, Inc. (‘Montara’), a therapeutics company aiming to revolutionize the discovery and development of brain-targeting drugs, announced today the closing of an oversubscribed... |
| 29.07.2024 | BioAge Announces First Patient Dosed in the STRIDES Phase 2 Clinical Trial Evaluating Azelaprag as a Novel Treatment for Obesity in Combination with Tirzepatide | Trial to evaluate weight loss efficacy of azelaprag, an oral small molecule apelin receptor agonist that mimics key biological effects of exercise
STRIDES is being conducted in collaboration with Lilly’s Chorus clinical development organiza... |
| 24.07.2024 | Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia | TPN-101 treatment reduced the rate of decline of Vital Capacity by 50% compared to placebo after 24 weeks, an objective respiratory measure that correlates with mortality in patients with ALS
Treatment with TPN-101 also showed a slowing of ... |
| 24.07.2024 | Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix | IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and ... |
| 12.07.2024 | UK needs Covid-style push on dementia drugs, says ex-head of vaccine taskforce | Kate Bingham says ageing population means tackling dementia must be treated as economic imperative |
| 10.07.2024 | Quell Therapeutics Appoints Experienced Biopharma Leader Luke Beshar as Independent Chair of its Board of Directors | London, UK – July 10, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces the appointment of Luke Beshar a... |
| 02.07.2024 | Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics | HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announces the appointment of Steven James to its Board of Directors. Mr. James brings over... |
| 02.07.2024 | ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center | LONDON — July 1, 2024 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial i... |
| 02.07.2024 | Sitryx announces leadership transition | Oxford, UK – 2 July 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of therapies for chronic autoimmune and inflammatory diseases, today announ... |
| 26.06.2024 | TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases | SOUTH SAN FRANCISCO, June 26, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that collaboration partner Eli Lilly and Company (“Lilly”) h... |
| 24.06.2024 | Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure | NAPERVILLE, Ill., June 24, 2024 /PRNewswire/ -- Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at the intersection of digital health and medtech, today announced Premarket Approval (PMA... |
| 10.06.2024 | Mission-Driven Dementia Funding with DDF's Jonathan Behr | If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back... |
| 03.06.2024 | QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD | QRL-204 is a splice-switching ASO generated through QurAlis’ FlexASO™ Platform; represents Lilly’s first program targeting UNC13A in ALS and FTD
Parties to also collaborate to leverage QurAlis’ ALS and ASO development expertise to advance Q... |
| 30.05.2024 | Harness Therapeutics appoints Leading World Experts in Neurodegenerative Diseases to its Scientific Advisory Board (SAB) | Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme HRN001
Cambridge, UK, May 30, 2024: Harness Therapeutics, a biotechnology company... |
| 29.05.2024 | SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion | LONDON, BOSTON, 29 May 2024 2pm UK - SV Health Investors, a leading transatlantic venture capital and growth equity firm, is pleased to announce that EyeBio and Merck & Co. (“MSD”) have entered into a definitive agreement under which MS... |
| 29.05.2024 | Merck signs $3bn deal for Kate Bingham-backed eye disease biotech | US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness |
| 28.05.2024 | Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium | Cambridge, UK, May 23, 2024 – Amphista Therapeutics (“Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the unveiling of a new mechanism of action for the degradation of BRD9, an emerging... |
| 21.05.2024 | Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation | CAMBRIDGE, Mass., May 21, 2024 /PRNewswire/ -- Nanopath Inc., a point-of-care diagnostics company enabling high-quality molecular testing in minutes, announced today that it was awarded $4 million in federal funding. The company was awarded... |
| 21.05.2024 | Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy | Designation Supports Accelerated Drug Development for PSP
TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers of Neurodegeneration and Neuroinflammation in PSP
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Transposon ... |
| 15.05.2024 | Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain | May 14, 2024, 09:00 ET
After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indicat... |
| 08.05.2024 | Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases | Sacramento, May 8, 2024 (GLOBE NEWSWIRE) — Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction, today announced positive preclinical d... |
| 02.05.2024 | Cerevance Achieves First Milestone in Research Collaboration with MSD | BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first milestone in its research collaboration with ... |
| 30.04.2024 | The Sean M. Healey & AMG Center for ALS and Prilenia Therapeutics Announce First Participant Enrolled in NIH-Sponsored ACT for ALS Expanded Access Protocol for Pridopidine | BOSTON―The Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with Prilenia Therapeutics B.V is thrilled to announce the enrollment of the first participant in the National Institutes of Health (NIH) – Nation... |
| 29.04.2024 | Former SV Portfolio Company Deciphera acquired by Ono Pharmaceutical for $2.4B after biotech's Phase 3 win | Japanese drugmaker Ono Pharmaceutical is acquiring cancer-focused biotech Deciphera Pharmaceuticals for $2.4 billion, the companies announced Monday morning. |
| 25.04.2024 | Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others
Proceeds will advance Cerevance’s first-in-class pre-clinical and clinical programs, including i... |
| 24.04.2024 | Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair | Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles
Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutic... |
| 15.04.2024 | Pulmocide Announces Successful Results from the OPERA-S Study: a Phase 2 Safety Study with Inhaled Opelconazole | Inhaled opelconazole observed to be generally well tolerated in this study as prophylaxis against pulmonary aspergillosis in lung transplant patients
Discontinuations due to drug-related adverse events and drug-drug interactions lower in th... |
| 15.04.2024 | AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations | LONDON — APRIL 15, 2024 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that the first patient has been treated in t... |
| 12.04.2024 | Prilenia to Present Latest Research from its Pridopidine Programs for Huntington Disease and ALS at AAN 2024 | Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures important to patients and families
--
Data to be presented at the American Academy of Ne... |
| 10.04.2024 | Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis | Oxford, UK – 10 April 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on modulating immune cell metabolism to advance a new generation of therapies for chronic autoimmune and inflammatory diseases, has nomina... |
| 08.04.2024 | Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants | - Bacterial contamination of orthopaedic implants is a growing clinical challenge that burdens the healthcare system and can lead to dangerous, potentially fatal complications for patients.
PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- On... |
| 08.04.2024 | Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at AC... | BOSTON, Mass., April 8, 2024 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced... |
| 07.04.2024 | Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024 | -- First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver
-- Data shows direct binding of small molecules to c-MYC RNA... |
| 02.04.2024 | A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough | Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VC efforts like the Dementia Discovery Fund have invested in the next wave of therapies. |
| 02.04.2024 | Miach Orthopaedics Raises $20 Million in Series B Extension | Miach Orthopaedics Raises $20 Million in Series B Extension
The Major League Soccer Players Association (MLSPA), SV Health Investors and Aperture Venture Partners Join Existing Investors to Support Commercial Expansion and Clinical Activiti... |
| 28.03.2024 | Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program | — Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers —
FOSTER CITY, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)-- Gi... |
| 27.03.2024 | Cumulus Neuroscience Receives Innovate UK Small Business Research Initiative (SBRI) Grant Focused on Clinical Biomarker Tools and Technologies for Dementia | Funded by a nearly £1M (~$1.25M USD) grant, this research will enable development and validation of an artificial intelligence (AI) diagnostic tool that improves the accuracy of blood biomarkers.
Cumulus Neuroscience today announced receipt... |
| 26.03.2024 | Dementia Discovery Fund Look Ahead: 2024 is shaping up to be another big year in the fight against dementia | As we approach the second quarter of 2024, the SV Health Investors Partners investing out of the Dementia Discovery Fund (DDF) have summarised the key themes and topics that are likely to be front and centre over the next nine months:
1. St... |
| 26.03.2024 | SV Biotech launches its inaugural ESG and Impact Report | SV Health Investors ESG and Impact Report SV Biotech Funds |
| 21.03.2024 | UK dementia adviser [Ruth McKernan] wants half a million volunteers for clinical trials | Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs |
| 14.03.2024 | Cumulus Neuroscience Announces First Patient Enrolled in AccelADx Electroencephalogram (EEG) Study for Early Detection of Alzheimer's Dementia | NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer's Dementia.
Cumulus Neuroscience today announced the enrollment of the first patient in a major research collaboration with the Universities of Bath and Bri... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | -Following positive pre-submission meetings with regulators, Prilenia plans to submit its MAA for pridopidine in Huntington’s disease (HD) in mid-2024-
-If approved, pridopidine could be commercially available to patients in Europe as early... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in multiple tumor types with significant unmet need —
— First data disclosure from the Company’s RNA-targeting small molecule platform and its pro... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 08.03.2024 | On International Women's Day SV Venture Partner Ruth McKernan reflects on some achievements of SV biotech portfolio companies | On International Women’s Day it is extremely pleasing to note the vast majority of SV Health Investor’s biotech portfolio companies with women in their C-suite, many being led by female CEOs. It is one of the many reasons I was drawn to wor... |
| 04.03.2024 | QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia | UNC13A is an essential regulator of neurotransmitter release at synapses; mis-splicing is a critical RNA alteration occurring in up to 63 percent of all ALS patients and up to one-third of all FTD cases
Preclinical data to be featured in a ... |
| 23.02.2024 | How Precision Neuroscience and Drug Synergies Could Revolutionize Neurology | In a recent interview with Laurence Barker, a partner at SV Health Investors and a key figure in the Dementia Discovery Fund franchise, we discussed the evolving landscape of biotechnology and the strides toward tackling dementia and other ... |
| 22.02.2024 | Precision Neuroscience: A New Frontier in Dementia Research and Beyond | Dive into the fascinating world of precision neuroscience with Laurence Barker, Partner at Dementia Discovery Fund - SV Health Investors |
| 13.02.2024 | Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M | CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of ... |
| 13.02.2024 | BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers | BioAge Labs has reeled in the biotech industry’s largest private financing round so far in 2024 as the California startup goes full throttle on the hottest areas in obesity drug development: oral formulations and muscle preservation. |
| 13.02.2024 | EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting | Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration. Proof of concept established with strong visual and anatomic out... |
| 13.02.2024 | EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases | EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa trial as a monotherapy and in combination with Regeneron’s Eylea, prompting preliminary plans for a potential registrational study in retin... |
| 13.02.2024 | BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics | February 13, 2024 08:00 AM Eastern Standard Time
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of ag... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Stu... | SAN DIEGO, Feb. 12, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases including Alzheimer's ... |
| 07.02.2024 | Kate Bingham Participates in The Times' Health Commission Report Summit | The government’s former chief scientific adviser [Sir Patrick Vallance] told The Times Health Commission that the NHS must learn from the Covid vaccine taskforce and take risks to improve |
| 24.01.2024 | Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders | Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces the achievement of two compelling new data sets with its nex... |
| 19.01.2024 | Prilenia Announces Clinical Data in Support of its Plans to Initiate Global Phase 3 Study in ALS | NAARDEN, Netherlands and WALTHAM, Mass., 19 January 2024 --- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 12.01.2024 | The deal flow just gets better and better”: how Europe's startups are pushing progress for neurodegenerative diseases | With two new drugs emerging in 2023, could this be the year for neurodegenerative startups to shine? |
| 11.01.2024 | SV investment has resulted in the approval of 24 novel therapeutics | SV approved therapeutics |
| 08.01.2024 | SV is hiring: Analyst / Associate - Biotech team | Position Title: Analyst / Associate - Biotech team |
| 08.01.2024 | SV is hiring: Executive Assistant | Position Title: Executive Assistant – Venture Capital/Growth Equity Firm |
| 04.01.2024 | SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner | LONDON - BOSTON, 04 January 2024 (GLOBE NEWSWIRE) - SV Health Investors, a leading transatlantic venture capital and growth equity firm, is pleased to announce that it is bolstering its senior biotech team with the appointments of Nikola Tr... |
| 04.01.2024 | Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases | Oxford, UK – 4 January 2024 – Sitryx Therapeutics (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics for chronic autoimmune and inflammatory diseases, today announces... |
| 04.01.2024 | Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC) | Oxford, UK – January 04, 2024. Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen dis... |
| 03.01.2024 | QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing | New location in Leiden, The Netherlands will serve as hub for European operations and production of QurAlis' products for clinical trials through commercialization |
| 20.12.2023 | Perfuze® Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment | Galway, Ireland, December 20, 2023 –Perfuze, a private medical device company dedicated to developing pioneering technology to treat acute ischemic stroke, proudly announces FDA clearance for the Millipede 070 Aspiration Catheter and the 2n... |
| 13.12.2023 | Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership | Atlanta, GA (December 13, 2023) –Hightop Health, a premier outpatient mental health platform, today announced the appointment of Carol Vallone as its Independent Board Director. |
| 28.11.2023 | Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases | Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to develop next generation therapeutics for the treatment of neurod... |
| 21.11.2023 | Merck to Acquire Caraway Therapeutics, Inc. | Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases |
| 21.11.2023 | Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck | This transaction highlights DDF’s attractive strategy of investing in novel therapeutics for dementia, a rapidly escalating public health crisis. |
| 14.11.2023 | EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases | EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support accelerated development of its innovative ... |
| 14.11.2023 | Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and ... | 24-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease |
| 13.11.2023 | Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease | Boston, MA – November 13, 2023 – Cerevance, a company focused on developing novel precision therapeutics for central nervous system (CNS) diseases, today announced that the first subject has been dosed in the Phase 2 clinical study of CVN42... |
